- West Pharmaceutical Services (WST, Financial) reported a Q1 2025 revenue increase of 0.4% to $698.0 million, with an organic net sales growth of 2.1%.
- The company raised its full-year 2025 net sales guidance to $2.945-2.975 billion and adjusted-diluted EPS guidance to $6.15-6.35.
- A third-quarter 2025 dividend of $0.21 per share was declared, payable on August 6, 2025.
West Pharmaceutical Services (WST) announced its financial results for the first quarter of 2025, marking a slight increase in net sales to $698.0 million, up by 0.4% from last year, and achieving an organic net sales growth of 2.1%. Despite this growth, the company's reported-diluted earnings per share (EPS) decreased to $1.23 from $1.55 compared to the same period in the previous year. Adjusted-diluted EPS also saw a decline, reaching $1.45, down from $1.56.
The company has updated its full-year 2025 financial outlook, raising its net sales guidance to a range of $2.945 billion to $2.975 billion, reflecting confidence in maintaining positive trends despite new tariff challenges estimated to influence the results by $20-25 million. The adjusted-diluted EPS guidance has been upgraded to $6.15-6.35, acknowledging the impact of favorable foreign currency movements.
Analyzing segment performance, the Proprietary Products segment grew by 0.6%, reaching $563.0 million, while Contract-Manufactured Products saw a slight decline of 0.7% to $135.0 million. The company completed a stock repurchase of 550,281 shares for $133.5 million, with an average price of $242.63 per share.
West also declared a third-quarter 2025 dividend of $0.21 per share, to be paid on August 6, 2025, to shareholders recorded as of July 30, 2025. This move reflects the company's commitment to delivering consistent value to its stakeholders while actively navigating operational challenges and macroeconomic uncertainties.
